Medpace Holdings Inc vs Zeta Global Holdings Corp — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Zeta Global Holdings Corp trades at $21.07 (market cap $5.32B). The key difference: Medpace Holdings Inc is far larger — about 2.8× Zeta Global Holdings Corp's market cap. Which is the better fit depends on your goals.
| MEDP | ZETA | |
|---|---|---|
Market Cap | $15.08B | $5.32B |
Sector | Technology | Technology |
52-Week High | $620.59 | $25.24 |
52-Week Low | $308.88 | $14.55 |
Enterprise Value | $14.55B | $5.23B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
ZETA trades at $21.34, down 1.57% on the day, with a bullish technical signal from moving averages and strong analyst support (73% buy ratings). The company reported Q1 2026 earnings of $0.14 per share, beating estimates, and is pivoting toward AI infrastructure through partnerships with Palantir and OpenAI. Revenue grew to $1.30 billion in 2025, though net income remained negative at -$31.51 million.
The outlook is positive due to AI-driven growth and strategic partnerships, but risks include margin pressure and integration challenges. The consensus price target of $27.50 suggests significant upside potential if execution aligns with bullish expectations, though negative profitability metrics warrant caution.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →